Hormonal risk factors and breast cancer prognosis and survival by PAM50 molecular subtype.

被引：0
|
作者：
Kwan, Marilyn L. [1 ]
Sweeney, Carol [2 ]
Habel, Laurel A. [1 ]
Weltzien, Erin [1 ]
Castillo, Adrienne [1 ]
Davis, Carole [2 ]
Factor, Rachel E. [2 ]
Kroenke, Candyce H. [1 ]
Shakespear, Kaylynn [2 ]
Quesenberry, Charles P. [1 ]
Stijleman, Inge J. [2 ]
Bernard, Philip S. [2 ]
Kushi, Lawrence H. [1 ]
Caan, Bette J. [1 ]
机构：
[1] Kaiser Permanente No Calif, Oakland, CA USA
[2] Univ Utah, Salt Lake City, UT USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-LB-29
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB29
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Proteomic profile of PAM50 intermediate risk early breast cancers
    Hajjaji, N.
    Aboulouard, S.
    Robin, Y. M.
    Bertin, D.
    Fournier, I.
    Bonneterre, J.
    Salzet, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [22] Multi-Omic Regulation of the PAM50 Gene Signature in Breast Cancer Molecular Subtypes
    Ochoa, Soledad
    de Anda-Jauregui, Guillermo
    Hernandez-Lemus, Enrique
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [23] Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer
    Lien, Tonje
    Ohnstad, Hege Oma
    Lingjaerde, Ole Christian
    Vallon-Christersson, Johan
    Aaserud, Marit
    Sveli, My Anh Tu
    Borg, Ake
    OSBREAC, Oystein
    Garred, Oystein
    Borgen, Elin
    Naume, Bjorn
    Russnes, Hege
    Sorlie, Therese
    CANCERS, 2021, 13 (23)
  • [24] Survival following locoregional recurrence in breast cancer by clinical subtype.
    Allen, Kirsten
    Lohrisch, Caroline A.
    Le, Dan
    Diocee, Rekha M.
    Speers, Caroline
    Nichol, Alan
    Taylor, Sara Kristina
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] PAM50 breast cancer subtyping and risk of recurrence in a population-based cohort.
    Bernard, Philip
    Weltzien, Erin
    Stijleman, Inge
    Kroenke, Candyce H.
    Davis, Carole
    Kwan, Marilyn L.
    Quesenberry, Charles
    Castillo, Adrienne
    Habel, Laurel
    Factor, Rachel
    Kushi, Larry
    Sweeney, Carol
    Caan, Bette
    CANCER RESEARCH, 2013, 73 (08)
  • [26] Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis in luminal breast cancer
    Velazco, Joanna Ines Lopez
    Otano, Maria
    Lacambra, Inazio
    Elorriaga, Kepa
    Lahuerta, Ainhara
    Martinez, Ana
    Segur, Virginia
    Manzano, Sara
    Prat, Aleix
    Caffarel, Maria
    Urruticoechea, Ander
    CANCER RESEARCH, 2022, 82 (04)
  • [27] Comparison of the pam50 intrinsic subtypes with immunohistochemistry in breast cancer patients
    Honrado, E.
    Saez Alvarez, S.
    Lopez Gonzalez, A.
    Tavara Silva, B. I.
    Prieto Dominguez, L.
    Martinez Martinez, J.
    Lopez Flores, M. A.
    Garcia Palomo, A.
    VIRCHOWS ARCHIV, 2020, 477 : S47 - S47
  • [28] Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study
    Troester, Melissa A.
    Sun, Xuezheng
    Allott, Emma H.
    Geradts, Joseph
    Cohen, Stephanie M.
    Tse, Chiu-Kit
    Kirk, Erin L.
    Thorne, Leigh B.
    Mathews, Michelle
    Li, Yan
    Hu, Zhiyuan
    Robinson, Whitney R.
    Hoadley, Katherine A.
    Olopade, Olufunmilayo I.
    Reeder-Hayes, Katherine E.
    Earp, H. Shelton
    Olshan, Andrew F.
    Carey, Lisa A.
    Perou, Charles M.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (02):
  • [29] PAM50 subtype admixture in individual breast cancers and the relationship of this intratumoral heterogeneity to clinical variables
    Gann, Peter H.
    Kumar, Neeraj
    Zhao, Dan
    Sethi, Amit
    CANCER RESEARCH, 2018, 78 (13)
  • [30] Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)
    Gilcrease, M. Z.
    BREAST DISEASES, 2016, 27 (02): : 130 - 131
12345